Christopher Liu
Stock Analyst at Lucid Capital
(3.77)
# 2,029
Out of 4,609 analysts
152
Total ratings
43.7%
Success rate
8.8%
Average return
Main Sectors:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCT Nuvectis Pharma | Maintained: Buy | $22 → $34 | $18.86 | +80.28% | 3 | Aug 5, 2026 | |
| CRDF Cardiff Oncology | Maintained: Buy | $14 → $4 | $0.9463 | +322.70% | 2 | Jun 5, 2026 | |
| NXTC NextCure | Maintained: Buy | $25 | $4.96 | +404.03% | 2 | Jun 2, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $50 | $24.26 | +106.10% | 1 | May 28, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $5 | $1.21 | +314.94% | 1 | May 18, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $14 | $5.42 | +158.30% | 1 | Mar 2, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $42 → $6 | $1.84 | +226.09% | 2 | Feb 4, 2026 | |
| ANL Adlai Nortye | Initiated Coverage: Buy | $11 | $13.24 | -16.92% | 1 | Jan 29, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $50 | $17.09 | +192.57% | 1 | Dec 15, 2025 | |
| IPHA Innate Pharma | Initiated Coverage: Buy | $8 | $1.77 | +351.98% | 1 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $15.23 | +31.32% | 1 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $4.00 | +125.00% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $2.66 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.70 | n/a | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $19 → $37 | $53.56 | n/a | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $36 | $24.69 | n/a | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $2.95 | n/a | 1 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $36.35 | n/a | 7 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $41.59 | n/a | 28 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $19.61 | n/a | 4 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.60 | n/a | 14 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $77 | $8.48 | n/a | 22 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $15.68 | n/a | 12 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $11.77 | n/a | 2 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $34.49 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $27 | $5.06 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.28 | n/a | 2 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.50 | n/a | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $12.69 | n/a | 2 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.9199 | n/a | 1 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.001 | n/a | 2 | Jul 6, 2018 |
Nuvectis Pharma
Aug 5, 2026
Maintained: Buy
Price Target: $22 → $34
Current: $18.86
Upside: +80.28%
Cardiff Oncology
Jun 5, 2026
Maintained: Buy
Price Target: $14 → $4
Current: $0.9463
Upside: +322.70%
NextCure
Jun 2, 2026
Maintained: Buy
Price Target: $25
Current: $4.96
Upside: +404.03%
Faeth Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $24.26
Upside: +106.10%
Actuate Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $5
Current: $1.21
Upside: +314.94%
Relmada Therapeutics
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $5.42
Upside: +158.30%
Tvardi Therapeutics
Feb 4, 2026
Upgraded: Buy
Price Target: $42 → $6
Current: $1.84
Upside: +226.09%
Adlai Nortye
Jan 29, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $13.24
Upside: -16.92%
Ascentage Pharma Group International
Dec 15, 2025
Initiated Coverage: Buy
Price Target: $50
Current: $17.09
Upside: +192.57%
Innate Pharma
Oct 23, 2025
Initiated Coverage: Buy
Price Target: $8
Current: $1.77
Upside: +351.98%
Sep 26, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $15.23
Upside: +31.32%
Sep 18, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $4.00
Upside: +125.00%
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $2.66
Upside: n/a
May 28, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.70
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $19 → $37
Current: $53.56
Upside: n/a
Apr 9, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $24.69
Upside: n/a
Jan 27, 2025
Maintained: Buy
Price Target: $20
Current: $2.95
Upside: n/a
Feb 21, 2024
Reiterated: Buy
Price Target: $50
Current: $36.35
Upside: n/a
Feb 20, 2024
Maintained: Buy
Price Target: n/a
Current: $41.59
Upside: n/a
Feb 13, 2024
Maintained: Buy
Price Target: $18
Current: $19.61
Upside: n/a
Dec 13, 2023
Reiterated: Buy
Price Target: $14
Current: $3.60
Upside: n/a
Dec 8, 2023
Reiterated: Buy
Price Target: $70 → $77
Current: $8.48
Upside: n/a
Nov 9, 2023
Maintained: Hold
Price Target: $5
Current: $15.68
Upside: n/a
Aug 9, 2018
Rated: Buy
Price Target: $13
Current: $11.77
Upside: n/a
Aug 2, 2018
Rated: Hold
Price Target: n/a
Current: $34.49
Upside: n/a
Aug 2, 2018
Rated: Buy
Price Target: $27
Current: $5.06
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $25.28
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $0.50
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $12.69
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $0.9199
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $0.001
Upside: n/a